Invention Grant
- Patent Title: Extracellular matrix cancer vaccine adjuvant
-
Application No.: US11875698Application Date: 2007-10-19
-
Publication No.: US08802113B2Publication Date: 2014-08-12
- Inventor: William R. Wolter , Mark S. Suckow
- Applicant: William R. Wolter , Mark S. Suckow
- Applicant Address: US IN Notre Dame
- Assignee: University of Notre Dame
- Current Assignee: University of Notre Dame
- Current Assignee Address: US IN Notre Dame
- Agency: Husch Blackwell LLP
- Agent Denise L. Mayfield
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K9/14 ; A61K9/70 ; A61K39/00 ; A61K35/52

Abstract:
Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.
Public/Granted literature
- US20080260800A1 EXTRACELLULAR MATRIX CANCER VACCINE ADJUVANT Public/Granted day:2008-10-23
Information query